首页 > 最新文献

Clinical biochemistry最新文献

英文 中文
Diagnostic value of serum TSI levels in Graves’ disease and direct comparison of diagnostic performance with TRAb: A systematic review and meta-analysis 血清TSI水平对Graves病的诊断价值及其与TRAb诊断效果的直接比较:一项系统综述和荟萃分析
IF 2.1 3区 医学 Q2 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2025-08-09 DOI: 10.1016/j.clinbiochem.2025.110989
Ziyue Jiang , Shouxia Li , Li Yang , Xuedong Song , Xiaofang Zhang , Lili Guo , Jia Guo , Haili Zhang , Dingli Chen
This study aimed to systematically assess the diagnostic value of thyroid-stimulating immunoglobulin on the Siemens Immulite platform (the TSI assay) and to conduct a direct comparison with thyrotropin receptor antibodies on the Roche cobas platform (the TRAb assay) for the diagnosis of Graves’ disease (GD). We performed systematic literature searches across multiple databases. Following strict screening, we identified 20 eligible clinical studies that evaluated the diagnostic value of the TSI assay, either alone or in comparison with the TRAb assay. Using random-effects models, we calculated pooled estimates of sensitivity (SEN), specificity (SPE), positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odds ratio (DOR). Diagnostic accuracy was further evaluated through summary receiver operating characteristic curve analysis. The findings revealed that the TSI assay demonstrated excellent diagnostic accuracy, with pooled SEN of 0.933 (95 % CI: 0.924 − 0.941), SPE of 0.961 (95 % CI: 0.956 − 0.964), PLR of 24.078 (95 % CI: 16.727 − 34.659), NLR of 0.036 (95 % CI: 0.020 − 0.066), and DOR of 778.29 (95 % CI: 343.45 − 1763.67), supported by an area under the curve (AUC) of 0.9919. In direct comparison to the TRAb assay, the TSI assay showed slightly better SEN (0.967 vs. 0.889), DOR (1310.03 vs. 692.73), and NLR (0.023 vs. 0.046), comparable SPE (0.964 vs. 0.959) and PLR (29.954 vs. 30.066), and higher AUC (0.9963 vs. 0.9899). These results conclusively demonstrate that the TSI assay shows high sensitivity and specificity in the diagnosis of GD, exceeding or at least comparable to TRAb, making it a valuable tool for clinical diagnosis.
本研究旨在系统评价促甲状腺免疫球蛋白在Siemens Immulite平台(TSI法)上的诊断价值,并与Roche cobas平台(TRAb法)上的促甲状腺激素受体抗体对Graves病(GD)的诊断价值进行直接比较。我们在多个数据库中进行了系统的文献检索。经过严格筛选,我们确定了20项符合条件的临床研究,评估TSI检测的诊断价值,无论是单独使用还是与TRAb检测进行比较。使用随机效应模型,我们计算了敏感性(SEN)、特异性(SPE)、阳性似然比(PLR)、阴性似然比(NLR)和诊断优势比(DOR)的汇总估计。通过综合受试者工作特征曲线分析进一步评价诊断准确性。结果表明,TSI法具有良好的诊断准确性,其综合SEN为0.933 (95% CI: 0.924 ~ 0.941), SPE为0.961 (95% CI: 0.956 ~ 0.964), PLR为24.078 (95% CI: 16.727 ~ 34.659), NLR为0.036 (95% CI: 0.020 ~ 0.066), DOR为778.29 (95% CI: 343.45 ~ 1763.67),曲线下面积(AUC)为0.9919。与TRAb法直接比较,TSI法的SEN (0.967 vs. 0.889)、DOR (1310.03 vs. 692.73)、NLR (0.023 vs. 0.046)、SPE (0.964 vs. 0.959)和PLR (29.954 vs. 30.066)略好,AUC (0.9963 vs. 0.9899)更高。这些结果最终表明,TSI检测在诊断GD方面具有很高的敏感性和特异性,超过或至少与TRAb相当,使其成为临床诊断的有价值的工具。
{"title":"Diagnostic value of serum TSI levels in Graves’ disease and direct comparison of diagnostic performance with TRAb: A systematic review and meta-analysis","authors":"Ziyue Jiang ,&nbsp;Shouxia Li ,&nbsp;Li Yang ,&nbsp;Xuedong Song ,&nbsp;Xiaofang Zhang ,&nbsp;Lili Guo ,&nbsp;Jia Guo ,&nbsp;Haili Zhang ,&nbsp;Dingli Chen","doi":"10.1016/j.clinbiochem.2025.110989","DOIUrl":"10.1016/j.clinbiochem.2025.110989","url":null,"abstract":"<div><div>This study aimed to systematically assess the diagnostic value of thyroid-stimulating immunoglobulin on the Siemens Immulite platform (the TSI assay) and to conduct a direct comparison with thyrotropin receptor antibodies on the Roche cobas platform (the TRAb assay) for the diagnosis of Graves’ disease (GD). We performed systematic literature searches across multiple databases. Following strict screening, we identified 20 eligible clinical studies that evaluated the diagnostic value of the TSI assay, either alone or in comparison with the TRAb assay. Using random-effects models, we calculated pooled estimates of sensitivity (SEN), specificity (SPE), positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odds ratio (DOR). Diagnostic accuracy was further evaluated through summary receiver operating characteristic curve analysis. The findings revealed that the TSI assay demonstrated excellent diagnostic accuracy, with pooled SEN of 0.933 (95 % CI: 0.924 − 0.941), SPE of 0.961 (95 % CI: 0.956 − 0.964), PLR of 24.078 (95 % CI: 16.727 − 34.659), NLR of 0.036 (95 % CI: 0.020 − 0.066), and DOR of 778.29 (95 % CI: 343.45 − 1763.67), supported by an area under the curve (AUC) of 0.9919. In direct comparison to the TRAb assay, the TSI assay showed slightly better SEN (0.967 vs. 0.889), DOR (1310.03 vs. 692.73), and NLR (0.023 vs. 0.046), comparable SPE (0.964 vs. 0.959) and PLR (29.954 vs. 30.066), and higher AUC (0.9963 vs. 0.9899). These results conclusively demonstrate that the TSI assay shows high sensitivity and specificity in the diagnosis of GD, exceeding or at least comparable to TRAb, making it a valuable tool for clinical diagnosis.</div></div>","PeriodicalId":10172,"journal":{"name":"Clinical biochemistry","volume":"139 ","pages":"Article 110989"},"PeriodicalIF":2.1,"publicationDate":"2025-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144810234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Best practice guidelines on reference interval harmonization in Canada: Evidence-based recommendations from the CSCC working group on reference interval harmonization (CSCC WG-hRI) 加拿大参考区间协调最佳实践指南:CSCC参考区间协调工作组(CSCC WG-hRI)提出的基于证据的建议。
IF 2.1 3区 医学 Q2 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2025-08-05 DOI: 10.1016/j.clinbiochem.2025.110986
Mary Kathryn Bohn , Dana Nyholt , Cynthia Balion , George Cembrowski , Christine Collier , Vincent De Guire , Victoria Higgins , Benjamin Jung , Olivia Landon , Zahraa Mohammed-Ali , David Seccombe , Jennifer Taher , Albert K.Y. Tsui , Allison A. Venner , Nicole White Al-Habeeb , Khosrow Adeli
Unnecessary variation in reference intervals across clinical laboratories increases the risk of inconsistent or misinformed clinical decision-making. Development of harmonized or common reference intervals for assays that demonstrate minimal bias across measurement procedures and laboratories is an important step towards standardized quality healthcare. The aim of this document is to recommend evidence-based harmonized reference intervals for routine clinical laboratory tests that can be implemented in hospital and community settings across Canada. The approach that was taken for these recommendations included several important steps. Candidate analytes for harmonization were selected based on documented traceability and external quality assessment performance. Two years of patient test result data for 16 routine clinical chemistry analytes were extracted from four provincial community laboratories across Canada. A robust indirect statistical algorithm was applied to assess the feasibility of harmonization and harmonized reference intervals were established for appropriate analytes. Derived harmonized reference intervals were compared to existing data from healthy individuals from Canadian and international studies. All recommended harmonized reference intervals were verified across nine Canadian laboratories that included all main manufacturers using serum and plasma samples collected from 60 healthy volunteers. Based on our findings, evidence-based harmonized reference intervals are recommended for 13 analytes, including: albumin (bromocresol green method only), alanine aminotransferase (ALT) with and without pyridoxal 5′-phosphate, alkaline phosphatase (ALP), calcium, carbon dioxide (total), chloride, creatinine, lactate dehydrogenase (LDH), phosphate, potassium (serum only), magnesium, total protein, and thyroid stimulating hormone (TSH). These recommendations will support national harmonization of laboratory reference intervals with the goal of improving and standardizing clinical decision-making and patient care across Canada.
临床实验室间参考间隔的不必要变化增加了不一致或错误的临床决策的风险。为在测量程序和实验室之间显示最小偏差的检测开发统一或通用参考区间是实现标准化质量医疗保健的重要一步。本文件的目的是推荐可在加拿大各地医院和社区环境中实施的常规临床实验室检测的循证统一参考区间。为这些建议所采取的办法包括几个重要步骤。根据记录的可追溯性和外部质量评估绩效选择用于协调的候选分析物。从加拿大四个省级社区实验室提取了两年来16项常规临床化学分析的患者检测结果数据。采用一种稳健的间接统计算法来评估协调的可行性,并为适当的分析物建立了协调的参考区间。将所得的统一参考区间与加拿大和国际研究中健康个体的现有数据进行比较。所有推荐的统一参考区间在加拿大9个实验室(包括所有主要制造商)中得到验证,这些实验室使用从60名健康志愿者收集的血清和血浆样本。基于我们的研究结果,推荐了13种分析物的循证统一参考间隔,包括:白蛋白(仅溴甲酚绿法)、谷丙转氨酶(ALT)(含或不含5'-磷酸吡啶醇)、碱性磷酸酶(ALP)、钙、二氧化碳(总)、氯化物、肌酐、乳酸脱氢酶(LDH)、磷酸盐、钾(仅血清)、镁、总蛋白和促甲状腺激素(TSH)。这些建议将支持全国实验室参考间隔的统一,以改善和标准化加拿大的临床决策和患者护理。
{"title":"Best practice guidelines on reference interval harmonization in Canada: Evidence-based recommendations from the CSCC working group on reference interval harmonization (CSCC WG-hRI)","authors":"Mary Kathryn Bohn ,&nbsp;Dana Nyholt ,&nbsp;Cynthia Balion ,&nbsp;George Cembrowski ,&nbsp;Christine Collier ,&nbsp;Vincent De Guire ,&nbsp;Victoria Higgins ,&nbsp;Benjamin Jung ,&nbsp;Olivia Landon ,&nbsp;Zahraa Mohammed-Ali ,&nbsp;David Seccombe ,&nbsp;Jennifer Taher ,&nbsp;Albert K.Y. Tsui ,&nbsp;Allison A. Venner ,&nbsp;Nicole White Al-Habeeb ,&nbsp;Khosrow Adeli","doi":"10.1016/j.clinbiochem.2025.110986","DOIUrl":"10.1016/j.clinbiochem.2025.110986","url":null,"abstract":"<div><div>Unnecessary variation in reference intervals across clinical laboratories increases the risk of inconsistent or misinformed clinical decision-making. Development of harmonized or common reference intervals for assays that demonstrate minimal bias across measurement procedures and laboratories is an important step towards standardized quality healthcare. The aim of this document is to recommend evidence-based harmonized reference intervals for routine clinical laboratory tests that can be implemented in hospital and community settings across Canada. The approach that was taken for these recommendations included several important steps. Candidate analytes for harmonization were selected based on documented traceability and external quality assessment performance. Two years of patient test result data for 16 routine clinical chemistry analytes were extracted from four provincial community laboratories across Canada. A robust indirect statistical algorithm was applied to assess the feasibility of harmonization and harmonized reference intervals were established for appropriate analytes. Derived harmonized reference intervals were compared to existing data from healthy individuals from Canadian and international studies. All recommended harmonized reference intervals were verified across nine Canadian laboratories that included all main manufacturers using serum and plasma samples collected from 60 healthy volunteers. Based on our findings, evidence-based harmonized reference intervals are recommended for 13 analytes, including: albumin (bromocresol green method only), alanine aminotransferase (ALT) with and without pyridoxal 5′-phosphate, alkaline phosphatase (ALP), calcium, carbon dioxide (total), chloride, creatinine, lactate dehydrogenase (LDH), phosphate, potassium (serum only), magnesium, total protein, and thyroid stimulating hormone (TSH). These recommendations will support national harmonization of laboratory reference intervals with the goal of improving and standardizing clinical decision-making and patient care across Canada.</div></div>","PeriodicalId":10172,"journal":{"name":"Clinical biochemistry","volume":"139 ","pages":"Article 110986"},"PeriodicalIF":2.1,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144788387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Waste management and environmental health impact: sustainable laboratory medicine as mitigating response 废物管理和环境健康影响:作为缓解对策的可持续实验室医学。
IF 2.1 3区 医学 Q2 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2025-08-04 DOI: 10.1016/j.clinbiochem.2025.110985
Nnenna Linda Nwobi , Gloria Oiyahumen Anetor , Joseph Chigbogu Nwobi , Godwin Osaretin Igharo , Anuoluwapo Victor Adeyemi , Tony Badrick , John Ibhagbemien Anetor
Unregulated and unsustainable human, industrial, and scientific activities generate various forms of waste which contribute immensely to the current rising global, multifaceted environmental health challenges. Laboratory medicine practices continue to be a key contributor to this menace with continuous generation of waste ranging from hazardous chemicals and toxic heavy metals to pathogenic biological waste, all of which pose significant risks to environmental and public health. While the wider scientific community has made significant attempts to adopt sustainable practices aligned with the United Nations Sustainable Development Goals, the laboratory medicine sector has lagged behind in implementing effective waste management strategies, particularly in developing countries, highlighting the need for targeted sustainable laboratory medicine practices. This review analysed relevant existing literature on the impact of laboratory waste on environmental health and explored sustainable laboratory medicine as a potential mitigating approach. The findings revealed that inefficient waste management significantly contributes to environmental degradation. Implementing sustainable laboratory (also known as green laboratory) practices such as use of eco-friendly materials, energy-efficient protocols, resource conservation, innovative waste minimisation, and treatment technologies appears to be a crucial framework that will mitigate the threat posed by laboratory-derived waste on environmental health. The review emphasised the need for a paradigm shift towards sustainable laboratory practices, advocating for comprehensive training, institutional commitment, and regulatory support to mitigate the environmental health impacts of laboratory-generated waste. This will ensure that laboratory medicine continues to advance without compromising public health or the planet.
不受管制和不可持续的人类、工业和科学活动产生各种形式的废物,极大地加剧了当前日益严重的全球性、多方面的环境卫生挑战。实验室医学实践仍然是造成这一威胁的一个主要因素,从危险化学品和有毒重金属到致病性生物废物等各种废物不断产生,所有这些都对环境和公众健康构成重大风险。虽然更广泛的科学界为采用符合联合国可持续发展目标的可持续做法做出了重大努力,但实验室医学部门在实施有效的废物管理战略方面落后,特别是在发展中国家,这突出表明需要有针对性的可持续实验室医学做法。本综述分析了实验室废弃物对环境健康影响的相关现有文献,并探讨了可持续实验室医学作为一种潜在的缓解方法。研究结果显示,废物管理效率低下严重加剧了环境退化。实施可持续的实验室(也称为绿色实验室)做法,如使用生态友好材料、节能协议、资源保护、创新的废物最小化和处理技术,似乎是一个关键框架,将减轻实验室产生的废物对环境健康构成的威胁。该审查强调需要将模式转向可持续的实验室做法,倡导全面培训、机构承诺和监管支持,以减轻实验室产生的废物对环境健康的影响。这将确保实验室医学在不损害公共卫生或地球的情况下继续发展。
{"title":"Waste management and environmental health impact: sustainable laboratory medicine as mitigating response","authors":"Nnenna Linda Nwobi ,&nbsp;Gloria Oiyahumen Anetor ,&nbsp;Joseph Chigbogu Nwobi ,&nbsp;Godwin Osaretin Igharo ,&nbsp;Anuoluwapo Victor Adeyemi ,&nbsp;Tony Badrick ,&nbsp;John Ibhagbemien Anetor","doi":"10.1016/j.clinbiochem.2025.110985","DOIUrl":"10.1016/j.clinbiochem.2025.110985","url":null,"abstract":"<div><div>Unregulated and unsustainable human, industrial, and scientific activities generate various forms of waste which contribute immensely to the current rising global, multifaceted environmental health challenges. Laboratory medicine practices continue to be a key contributor to this menace with continuous generation of waste ranging from hazardous chemicals and toxic heavy metals to pathogenic biological waste, all of which pose significant risks to environmental and public health. While the wider scientific community has made significant attempts to adopt sustainable practices aligned with the United Nations Sustainable Development Goals, the laboratory medicine sector has lagged behind in implementing effective waste management strategies, particularly in developing countries, highlighting the need for targeted sustainable laboratory medicine practices. This review analysed relevant existing literature on the impact of laboratory waste on environmental health and explored sustainable laboratory medicine as a potential mitigating approach. The findings revealed that inefficient waste management significantly contributes to environmental degradation. Implementing sustainable laboratory (also known as green laboratory) practices such as use of eco-friendly materials, energy-efficient protocols, resource conservation, innovative waste minimisation, and treatment technologies appears to be a crucial framework that will mitigate the threat posed by laboratory-derived waste on environmental health. The review emphasised the need for a paradigm shift towards sustainable laboratory practices, advocating for comprehensive training, institutional commitment, and regulatory support to mitigate the environmental health impacts of laboratory-generated waste. This will ensure that laboratory medicine continues to advance without compromising public health or the planet.</div></div>","PeriodicalId":10172,"journal":{"name":"Clinical biochemistry","volume":"139 ","pages":"Article 110985"},"PeriodicalIF":2.1,"publicationDate":"2025-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144768487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Monitoring free plasma hemoglobin in ECMO patients: a two-center comparative study of second-derivative spectrophotometry and hemolysis indexes ECMO患者游离血浆血红蛋白监测:二阶导数分光光度法与溶血指标的双中心比较研究。
IF 2.1 3区 医学 Q2 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2025-07-27 DOI: 10.1016/j.clinbiochem.2025.110983
Théo Sharaiha , Nolan Pellecuier , Sandrine Dabernat , Fouzi Mestari , Brigitte Colombiès , Emmanuel Richard , Rana Alkouri , Dominique Bonnefont-Rousselot , Benoit Rucheton , Marie-Lise Bats

Background and aims

Extracorporeal membrane oxygenation (ECMO) can induce massive intravascular hemolysis, commonly quantified by plasma free hemoglobin (fHb) measurement. While manual spectrophotometry using second derivative spectrophotometry (sDS) is the reference method, a recent assessment tool based on the hemolysis index (HI) was developed for fHb determination on different automated systems. This study compares the performance of two HI methods—on Roche Cobas c502 and Abbott Architect c16000—versus sDS in 83 ECMO patients.

Materials and methods

Method validation was performed on both automated HI systems, including determination of linearity, precision, and analytical interference from lipemia and icterus. Plasma fHb measurements in 83 ECMO patients from two hospital centers were compared between the two HI-derived methods and two manual sDS methods (at 415 nm and 578 nm).

Results

Both HI-automated methods showed excellent linearity (0.04–20 g/L) and reproducibility (CVs between 2.3 % and 6.3 %). However, they exhibited sensitivity to interference by high lipemic index, leading to underestimation of fHb for Abbott Architect and overestimation for Roche Cobas. In non-lipemic ECMO samples with fHb levels >0.10 g/L, a very good correlation was found between HI and sDS, especially at 578 nm. However, discrepancies were observed in lipemic samples, leading to clinically relevant biases for fHb values >0.50 g/L.

Conclusion

The Roche Cobas and Abbott Architect HI methods are reliable tools for monitoring fHb in ECMO patients, with good reproducibility and linearity. However, in the presence of significant lipemia, confirmation by sDS is recommended to ensure accurate assessment of hemolysis. This approach facilitates an efficient and automated monitoring of fHb, essential for daily managing ECMO-related complications and improving patient outcomes.
背景和目的:体外膜氧合(ECMO)可诱导大量血管内溶血,通常通过血浆游离血红蛋白(fHb)测量来定量。虽然使用二阶导数分光光度法(sDS)的手动分光光度法是参考方法,但最近开发了一种基于溶血指数(HI)的评估工具,用于在不同的自动化系统上测定血红蛋白。本研究比较了两种HI方法(Roche Cobas c502和Abbott Architect c16000)与sDS在83例ECMO患者中的表现。材料和方法:在两种自动化HI系统上进行方法验证,包括确定线性度、精密度以及血脂和黄疸的分析干扰。对来自两家医院中心的83名ECMO患者的血浆fHb测量进行了两种hi衍生方法和两种手动sDS方法(在415 nm和578 nm处)的比较。结果:两种方法均具有良好的线性关系(0.04 ~ 20 g/L)和重复性(CVs在2.3 % ~ 6.3 %之间)。然而,它们对高血脂指数的干扰表现出敏感性,导致雅培建筑师对fHb的低估和罗氏Cobas对fHb的高估。在fHb水平为>0.10 g/L的非血脂性ECMO样品中,HI和sDS之间存在非常好的相关性,特别是在578 nm处。然而,在血脂样本中观察到差异,导致fHb值>0.50 g/L的临床相关偏差。结论:Roche Cobas和Abbott Architect HI方法是监测ECMO患者fHb的可靠工具,具有良好的重现性和线性。然而,在存在明显的脂血症时,建议通过sDS确认以确保准确评估溶血。这种方法促进了fHb的有效和自动化监测,对于日常管理ecmo相关并发症和改善患者预后至关重要。
{"title":"Monitoring free plasma hemoglobin in ECMO patients: a two-center comparative study of second-derivative spectrophotometry and hemolysis indexes","authors":"Théo Sharaiha ,&nbsp;Nolan Pellecuier ,&nbsp;Sandrine Dabernat ,&nbsp;Fouzi Mestari ,&nbsp;Brigitte Colombiès ,&nbsp;Emmanuel Richard ,&nbsp;Rana Alkouri ,&nbsp;Dominique Bonnefont-Rousselot ,&nbsp;Benoit Rucheton ,&nbsp;Marie-Lise Bats","doi":"10.1016/j.clinbiochem.2025.110983","DOIUrl":"10.1016/j.clinbiochem.2025.110983","url":null,"abstract":"<div><h3>Background and aims</h3><div>Extracorporeal membrane oxygenation (ECMO) can induce massive intravascular hemolysis, commonly quantified by plasma free hemoglobin (fHb) measurement. While manual spectrophotometry using second derivative spectrophotometry (sDS) is the reference method, a recent assessment tool based on the hemolysis index (HI) was developed for fHb determination on different automated systems. This study compares the performance of two HI methods—on Roche Cobas c502 and Abbott Architect c16000—versus sDS in 83 ECMO patients.</div></div><div><h3>Materials and methods</h3><div>Method validation was performed on both automated HI systems, including determination of linearity, precision, and analytical interference from lipemia and icterus. Plasma fHb measurements in 83 ECMO patients from two hospital centers were compared between the two HI-derived methods and two manual sDS methods (at 415 nm and 578 nm).</div></div><div><h3>Results</h3><div>Both HI-automated methods showed excellent linearity (0.04–20 g/L) and reproducibility (CVs between 2.3 % and 6.3 %). However, they exhibited sensitivity to interference by high lipemic index, leading to underestimation of fHb for Abbott Architect and overestimation for Roche Cobas. In non-lipemic ECMO samples with fHb levels &gt;0.10 g/L, a very good correlation was found between HI and sDS, especially at 578 nm. However, discrepancies were observed in lipemic samples, leading to clinically relevant biases for fHb values &gt;0.50 g/L.</div></div><div><h3>Conclusion</h3><div>The Roche Cobas and Abbott Architect HI methods are reliable tools for monitoring fHb in ECMO patients, with good reproducibility and linearity. However, in the presence of significant lipemia, confirmation by sDS is recommended to ensure accurate assessment of hemolysis. This approach facilitates an efficient and automated monitoring of fHb, essential for daily managing ECMO-related complications and improving patient outcomes.</div></div>","PeriodicalId":10172,"journal":{"name":"Clinical biochemistry","volume":"139 ","pages":"Article 110983"},"PeriodicalIF":2.1,"publicationDate":"2025-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144741351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Low vacuum (3 mL) rapid serum tubes offer better protection from hemolysis than plasma separator tubes collected in the emergency department 低真空(3 mL)快速血清管比急诊科收集的血浆分离管能更好地防止溶血。
IF 2.1 3区 医学 Q2 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2025-07-26 DOI: 10.1016/j.clinbiochem.2025.110984
Emily Shang , Taylor Takasugi , Pedro Prellwitz , Cristina Figueroa Villalba , Rohit B. Sangal , Arjun K. Venkatesh , Lisa Maciejak , Erica Oberle , Joe M. El-Khoury

Introduction

Hemolysis is a major source of interference with laboratory testing, especially for the emergency department (ED), leading to longer turnaround times for test results, repeated blood draws, delay in care delivery, and increased hospital costs. Rapid serum tubes (RST) can reduce transport-induced hemolysis, especially for samples sent via the pneumatic tube system, as compared with plasma separator tubes (PST). Previously, studies testing the efficacy of RST used larger volume 5 mL tubes to compare to 4.5 mL PST tubes. In this study, a lower vacuum RST (3 mL) is compared to PST (3.5 mL) for hemolysis reduction.

Methods

Paired PST and RST blood samples from 47 ED patients were included in this study. RST and PST samples were sent via the pneumatic tube system and inspected for degree of clotting prior to centrifugation. All samples were tested within the hour for high-sensitivity troponin (hs-cTnT), hemolysis, lactate dehydrogenase, and potassium.

Results

Degree of hemolysis was significantly lower in fully clotted RSTs compared to PSTs (p = 0.0005). In RSTs that only partially clotted and PSTs, differences in hemolysis rates were non-significant (p = 0.273). The hs-cTnT levels in RST and PST are concordant with a slope of 0.96, an intercept of 1.01 ng/L and an R-squared value of 0.9318.

Conclusion

Fully clotted low-vacuum RSTs provide improved protection from transport-induced hemolysis compared to low-vacuum PSTs or partially clotted RSTs. Low-vacuum RSTs also provided more hemolysis protection than larger volume RSTs previously studied. Clot formation prior to transport is key to the protective mechanism of RST. Blood device manufacturers are encouraged to develop low vacuum RST for use by the ED and other areas with high hemolysis rates.
导读:溶血是干扰实验室检测的主要来源,特别是对急诊科(ED),导致检测结果的周转时间更长,重复抽血,延迟护理提供,并增加医院费用。与血浆分离管(PST)相比,快速血清管(RST)可以减少运输引起的溶血,特别是通过气动管系统发送的样本。以前,测试RST疗效的研究使用了更大体积的5 mL管,而4.5 mL PST管。在这项研究中,较低的真空RST(3 mL)与PST(3.5 mL)相比,可以减少溶血。方法:选取47例ED患者的PST和RST配对血样进行研究。RST和PST样品通过气动管系统发送,并在离心前检查凝块程度。所有样品在一小时内检测高敏肌钙蛋白(hs-cTnT)、溶血、乳酸脱氢酶和钾。结果:与PSTs相比,完全凝血的RSTs溶血程度显著降低(p = 0.0005)。在仅部分凝血的rst和pst中,溶血率差异无统计学意义(p = 0.273)。RST和PST中hs-cTnT水平一致,斜率为0.96,截距为1.01 ng/L, r平方值为0.9318。结论:与低真空PSTs或部分凝固的RSTs相比,完全凝固的低真空RSTs对运输诱导的溶血具有更好的保护作用。与先前研究的大容量RSTs相比,低真空RSTs也提供了更多的溶血保护。转运前的血栓形成是RST保护机制的关键。鼓励血液设备制造商开发低真空RST用于ED和其他高溶血率的领域。
{"title":"Low vacuum (3 mL) rapid serum tubes offer better protection from hemolysis than plasma separator tubes collected in the emergency department","authors":"Emily Shang ,&nbsp;Taylor Takasugi ,&nbsp;Pedro Prellwitz ,&nbsp;Cristina Figueroa Villalba ,&nbsp;Rohit B. Sangal ,&nbsp;Arjun K. Venkatesh ,&nbsp;Lisa Maciejak ,&nbsp;Erica Oberle ,&nbsp;Joe M. El-Khoury","doi":"10.1016/j.clinbiochem.2025.110984","DOIUrl":"10.1016/j.clinbiochem.2025.110984","url":null,"abstract":"<div><h3>Introduction</h3><div>Hemolysis is a major source of interference with laboratory testing, especially for the emergency department (ED), leading to longer turnaround times for test results, repeated blood draws, delay in care delivery, and increased hospital costs. Rapid serum tubes (RST) can reduce transport-induced hemolysis, especially for samples sent via the pneumatic tube system, as compared with plasma separator tubes (PST). Previously, studies testing the efficacy of RST used larger volume 5 mL tubes to compare to 4.5 mL PST tubes. In this study, a lower vacuum RST (3 mL) is compared to PST (3.5 mL) for hemolysis reduction.</div></div><div><h3>Methods</h3><div>Paired PST and RST blood samples from 47 ED patients were included in this study. RST and PST samples were sent via the pneumatic tube system and inspected for degree of clotting prior to centrifugation. All samples were tested within the hour for high-sensitivity troponin (hs-cTnT), hemolysis, lactate dehydrogenase, and potassium.</div></div><div><h3>Results</h3><div>Degree of hemolysis was significantly lower in fully clotted RSTs compared to PSTs (p = 0.0005). In RSTs that only partially clotted and PSTs, differences in hemolysis rates were non-significant (p = 0.273). The hs-cTnT levels in RST and PST are concordant with a slope of 0.96, an intercept of 1.01 ng/L and an R-squared value of 0.9318.</div></div><div><h3>Conclusion</h3><div>Fully clotted low-vacuum RSTs provide improved protection from transport-induced hemolysis compared to low-vacuum PSTs or partially clotted RSTs. Low-vacuum RSTs also provided more hemolysis protection than larger volume RSTs previously studied. Clot formation prior to transport is key to the protective mechanism of RST. Blood device manufacturers are encouraged to develop low vacuum RST for use by the ED and other areas with high hemolysis rates.</div></div>","PeriodicalId":10172,"journal":{"name":"Clinical biochemistry","volume":"139 ","pages":"Article 110984"},"PeriodicalIF":2.1,"publicationDate":"2025-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144728290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Metabolic score for insulin resistance (METS-IR) as a predictor of gestational diabetes: Findings from a prospective Iranian cohort study 胰岛素抵抗代谢评分(METS-IR)作为妊娠糖尿病的预测因子:来自伊朗前瞻性队列研究的发现
IF 2.1 3区 医学 Q2 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2025-07-25 DOI: 10.1016/j.clinbiochem.2025.110982
Safoura Rouholamin , Maryam Razavi , Reihaneh Pirjani , Mahroo Rezaeinejad

Background

Gestational diabetes mellitus (GDM) represents a significant metabolic challenge in pregnancy, with relevance for Middle Eastern populations showing high prevalence rates. The metabolic score for insulin resistance (METS-IR) has emerged as a potential early predictor, though its performance in Iranian populations remains underexplored.

Methods

In this prospective cohort study conducted at Arash Women’s Hospital, Tehran (2020–2023), we enrolled 1,845 pregnant women during their first trimester (<12 weeks gestation). Participants underwent comprehensive metabolic evaluation including calculation of METS-IR. GDM diagnosis was established at 24–28 weeks using 75-g oral glucose tolerance test per American Diabetes Association criteria. We employed modified Poisson regression with robust variance estimation to assess associations, adjusting for key confounders identified through directed acyclic graphs.

Results

The study population demonstrated a GDM incidence of 19.78 % (365/1845). METS-IR showed strong predictive capacity with area under the ROC curve (AUC) of 0.82 (95 % CI: 0.79, 0.83). At the optimal cutoff of 2.36 (95 % CI: 2.30–2.41), sensitivity reached 72 % (95 % CI: 67, 76 %) and specificity 76 % (95 % CI: 74, 78 %). Adjusted risk ratios revealed a striking dose–response relationship across quartiles: Q2 = 4.21 (2.16, 8.23), Q3 = 8.85 (4.66, 16.78), and Q4 = 18.94 (10.16, 35.29) compared to the reference quartile.

Conclusion

This study establishes METS-IR as a robust early predictor of GDM in Iranian women, demonstrating superior performance to conventional metabolic markers. The simple calculation and strong predictive validity suggest its potential for first-trimester risk stratification in clinical practice, particularly valuable in high-prevalence populations.
背景:妊娠期糖尿病(GDM)是妊娠期一项重要的代谢挑战,与中东地区高患病率人群相关。胰岛素抵抗的代谢评分(METS-IR)已成为潜在的早期预测指标,尽管其在伊朗人群中的表现仍未得到充分研究。方法:在德黑兰Arash妇女医院(2020-2023)进行的这项前瞻性队列研究中,我们招募了1845名妊娠早期的孕妇(结果:研究人群显示GDM发病率为19.78 %(365/1845)。met - ir具有较强的预测能力,ROC曲线下面积(AUC)为0.82(95 % CI: 0.79, 0.83)。在最佳截止点2.36(95 % CI: 2.30-2.41)时,灵敏度达到72 %(95 % CI: 67, 76 %),特异性达到76 %(95 % CI: 74, 78 %)。与参考四分位数相比,调整后的风险比显示四分位数之间存在显著的剂量-反应关系:Q2 = 4.21 (2.16,8.23),Q3 = 8.85 (4.66,16.78),Q4 = 18.94(10.16,35.29)。结论:本研究确立了met - ir作为伊朗女性GDM的可靠早期预测指标,表现出优于传统代谢指标的性能。简单的计算和强大的预测有效性表明其在临床实践中的早期妊娠风险分层潜力,特别是在高患病率人群中有价值。
{"title":"Metabolic score for insulin resistance (METS-IR) as a predictor of gestational diabetes: Findings from a prospective Iranian cohort study","authors":"Safoura Rouholamin ,&nbsp;Maryam Razavi ,&nbsp;Reihaneh Pirjani ,&nbsp;Mahroo Rezaeinejad","doi":"10.1016/j.clinbiochem.2025.110982","DOIUrl":"10.1016/j.clinbiochem.2025.110982","url":null,"abstract":"<div><h3>Background</h3><div>Gestational diabetes mellitus (GDM) represents a significant metabolic challenge in pregnancy, with relevance for Middle Eastern populations showing high prevalence rates. The metabolic score for insulin resistance (METS-IR) has emerged as a potential early predictor, though its performance in Iranian populations remains underexplored.</div></div><div><h3>Methods</h3><div>In this prospective cohort study conducted at Arash Women’s Hospital, Tehran (2020–2023), we enrolled 1,845 pregnant women during their first trimester (&lt;12 weeks gestation). Participants underwent comprehensive metabolic evaluation including calculation of METS-IR. GDM diagnosis was established at 24–28 weeks using 75-g oral glucose tolerance test per American Diabetes Association criteria. We employed modified Poisson regression with robust variance estimation to assess associations, adjusting for key confounders identified through directed acyclic graphs.</div></div><div><h3>Results</h3><div>The study population demonstrated a GDM incidence of 19.78 % (365/1845). METS-IR showed strong predictive capacity with area under the ROC curve (AUC) of 0.82 (95 % CI: 0.79, 0.83). At the optimal cutoff of 2.36 (95 % CI: 2.30–2.41), sensitivity reached 72 % (95 % CI: 67, 76 %) and specificity 76 % (95 % CI: 74, 78 %). Adjusted risk ratios revealed a striking dose–response relationship across quartiles: Q2 = 4.21 (2.16, 8.23), Q3 = 8.85 (4.66, 16.78), and Q4 = 18.94 (10.16, 35.29) compared to the reference quartile.</div></div><div><h3>Conclusion</h3><div>This study establishes METS-IR as a robust early predictor of GDM in Iranian women, demonstrating superior performance to conventional metabolic markers. The simple calculation and strong predictive validity suggest its potential for first-trimester risk stratification in clinical practice, particularly valuable in high-prevalence populations.</div></div>","PeriodicalId":10172,"journal":{"name":"Clinical biochemistry","volume":"139 ","pages":"Article 110982"},"PeriodicalIF":2.1,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144728291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
LRG and NGAL are potential diagnosis and disease activity biomarkers for inflammatory bowel disease LRG和NGAL是炎症性肠病的潜在诊断和疾病活动性生物标志物。
IF 2.5 3区 医学 Q2 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2025-07-22 DOI: 10.1016/j.clinbiochem.2025.110981
Dongdan Zhang , Yue Meng , Dan Li , Shaomei Zhu

Background

Neutrophil gelatinase-associated lipocalin (NGAL) and serum leucine-rich α-2 glycoprotein (LRG) are reported as potential biomarkers in inflammatory bowel disease (IBD), but the difference in diagnostic efficacy has not been reported. We aimed to investigate the clinical value of NGAL and LRG in IBD diagnosis and disease assessment.

Methods

One hundred IBD patients, including 75 Crohn’s disease (CD) and 25 ulcerative colitis, and 100 healthy controls were enrolled. The serum NGAL and LRG concentrations were quantified by enzyme linked immunosorbent assay. Receiver operating characteristic (ROC) curve analysis was used to evaluate their diagnostic performance.

Results

The serum concentrations of NGAL and LRG were significantly higher in IBD patients than in healthy controls (P < 0.001). Serum NGAL is significantly correlated with LRG (r = 0.574, P < 0.001). Serum LRG showed a better capacity to identify IBD with an area under the ROC curve (AUC) of 0.90 (sensitivity 89 %, specificity 78 %), compared to NGAL with an AUC of 0.84 (sensitivity 85 %, specificity 71 %). Additionally, serum NGAL and LRG were highly correlated with disease activity in CD patients (r = 0.865 and 0.878, P < 0.001), and gradually increased with disease activity severity (P < 0.05).

Conclusion

Serum NGAL and LRG are potential diagnostic and disease activity biomarkers for IBD, which have good clinical application value.
背景:中性粒细胞明胶酶相关脂钙蛋白(NGAL)和血清富亮氨酸α-2糖蛋白(LRG)被报道为炎症性肠病(IBD)的潜在生物标志物,但其诊断效果的差异尚未报道。我们旨在探讨NGAL和LRG在IBD诊断和疾病评估中的临床价值。方法:选取100例IBD患者,其中克罗恩病(CD) 75例,溃疡性结肠炎25例,对照组100例。采用酶联免疫吸附法测定血清NGAL和LRG浓度。采用受试者工作特征(ROC)曲线分析评价其诊断效果。结果:IBD患者血清NGAL和LRG浓度显著高于健康对照组(P )结论:血清NGAL和LRG是IBD潜在的诊断和疾病活动性生物标志物,具有良好的临床应用价值。
{"title":"LRG and NGAL are potential diagnosis and disease activity biomarkers for inflammatory bowel disease","authors":"Dongdan Zhang ,&nbsp;Yue Meng ,&nbsp;Dan Li ,&nbsp;Shaomei Zhu","doi":"10.1016/j.clinbiochem.2025.110981","DOIUrl":"10.1016/j.clinbiochem.2025.110981","url":null,"abstract":"<div><h3>Background</h3><div>Neutrophil gelatinase-associated lipocalin (NGAL) and serum leucine-rich α-2 glycoprotein (LRG) are reported as potential biomarkers in inflammatory bowel disease (IBD), but the difference in diagnostic efficacy has not been reported. We aimed to investigate the clinical value of NGAL and LRG in IBD diagnosis and disease assessment.</div></div><div><h3>Methods</h3><div>One hundred IBD patients, including 75 Crohn’s disease (CD) and 25 ulcerative colitis, and 100 healthy controls were enrolled. The serum NGAL and LRG concentrations were quantified by enzyme linked immunosorbent assay. Receiver operating characteristic (ROC) curve analysis was used to evaluate their diagnostic performance.</div></div><div><h3>Results</h3><div>The serum concentrations of NGAL and LRG were significantly higher in IBD patients than in healthy controls (<em>P</em> &lt; 0.001). Serum NGAL is significantly correlated with LRG (r = 0.574, <em>P</em> &lt; 0.001). Serum LRG showed a better capacity to identify IBD with an area under the ROC curve (AUC) of 0.90 (sensitivity 89 %, specificity 78 %), compared to NGAL with an AUC of 0.84 (sensitivity 85 %, specificity 71 %). Additionally, serum NGAL and LRG were highly correlated with disease activity in CD patients (r = 0.865 and 0.878, <em>P</em> &lt; 0.001), and gradually increased with disease activity severity (<em>P</em> &lt; 0.05).</div></div><div><h3>Conclusion</h3><div>Serum NGAL and LRG are potential diagnostic and disease activity biomarkers for IBD, which have good clinical application value.</div></div>","PeriodicalId":10172,"journal":{"name":"Clinical biochemistry","volume":"139 ","pages":"Article 110981"},"PeriodicalIF":2.5,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144706544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Navigating an unexpected creatinine result during a pre-intravenous contrast renal function workup 在静脉造影前肾功能检查中发现意外的肌酐结果。
IF 2.5 3区 医学 Q2 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2025-07-18 DOI: 10.1016/j.clinbiochem.2025.110979
Madhusudhanan Narasimhan, Kibibi Smith, Alagarraju Muthukumar

Background

Increasing chronic disease incidence drives intravenous (IV) contrast-based diagnostic imaging. While IV procedure is largely safe, contrast-induced neuropathy risk in patients with predisposing factors demand pre-IV renal assessment. Although common, point-of-care creatinine (POC) tests are prone to generating ambiguous results. This frequently result in time-consuming retests, rescheduled appointments, patient distress, and healthcare burdens.

Case Presentation

A diabetic, hypertensive, and chronic kidney diseased Caucasian male, aged 61, presented for a scheduled intravenous contrast-enhanced computed tomography scan. His initial POC-based creatinine result of 1.20 mg/dL (106.1 μmol/L) narrowly exceeded the reference interval (0.67–––1.17 mg/dL [59.2 – 103.5 μmol/L]). Given the patient’s pre-existing conditions, laboratory-based creatinine test was performed to reassure his renal function. The new result was found to be 0.95 mg/dL (84 μmol/L), which fell within the normal reference interval. This substantial disparity of 0.25 mg/dL (22.1 μmol/L; 20.8 %) between creatinine tests while delaying the intravenous procedure prompted the clinicians to request an in-depth laboratory investigation.

Conclusion

Comprehensive analysis using patient-centered metrics such as index of individuality, reference change value, and subject-based reference interval alleviated the concerns on his renal health and disparity in assay results (<0.3 mg/dL≡ <26.5 μmol/L) total allowable error limit), thus allowing intravenous contrast imaging.
背景:慢性疾病发病率的增加推动了静脉(IV)造影诊断成像。虽然静脉注射手术在很大程度上是安全的,但在有易感因素的患者中,造影剂诱导的神经病变风险需要在静脉注射前进行肾脏评估。虽然常见,但即时肌酸酐(POC)检测容易产生模棱两可的结果。这经常导致耗时的重新测试、重新安排预约、患者痛苦和医疗负担。病例介绍:糖尿病,高血压,慢性肾病高加索男性,61岁,提出了一个计划静脉对比增强计算机断层扫描。他最初基于poc的肌酐结果为1.20 mg/dL(106.1 μmol/L),略高于参考区间(0.67—1.17 mg/dL[59.2—103.5 μmol/L])。考虑到患者已有的疾病,我们进行了实验室肌酐测试以确保其肾功能。新结果为0.95 mg/dL(84 μmol/L),在正常参考区间内。0.25 mg/dL(22.1 μmol/L;20.8 %),同时延迟静脉注射手术,这促使临床医生要求进行深入的实验室调查。结论:采用以患者为中心的指标,如个体化指数、参考变化值和基于受试者的参考区间,进行综合分析,减轻了对其肾脏健康和检测结果差异的担忧。
{"title":"Navigating an unexpected creatinine result during a pre-intravenous contrast renal function workup","authors":"Madhusudhanan Narasimhan,&nbsp;Kibibi Smith,&nbsp;Alagarraju Muthukumar","doi":"10.1016/j.clinbiochem.2025.110979","DOIUrl":"10.1016/j.clinbiochem.2025.110979","url":null,"abstract":"<div><h3>Background</h3><div>Increasing chronic disease incidence drives intravenous (IV) contrast-based diagnostic imaging. While IV procedure is largely safe, contrast-induced neuropathy risk in patients with predisposing factors demand pre-IV renal assessment. Although common, point-of-care creatinine (POC) tests are prone to generating ambiguous results. This frequently result in time-consuming retests, rescheduled appointments, patient distress, and healthcare burdens.</div></div><div><h3>Case Presentation</h3><div>A diabetic, hypertensive, and chronic kidney diseased Caucasian male, aged 61, presented for a scheduled intravenous contrast-enhanced computed tomography scan. His initial POC-based creatinine result of 1.20 mg/dL (106.1 μmol/L) narrowly exceeded the reference interval (0.67–––1.17 mg/dL [59.2 – 103.5 μmol/L]). Given the patient’s pre-existing conditions, laboratory-based creatinine test was performed to reassure his renal function. The new result was found to be 0.95 mg/dL (84 μmol/L), which fell within the normal reference interval. This substantial disparity of 0.25 mg/dL (22.1 μmol/L; 20.8 %) between creatinine tests while delaying the intravenous procedure prompted the clinicians to request an in-depth laboratory investigation.</div></div><div><h3>Conclusion</h3><div>Comprehensive analysis using patient-centered metrics such as index of individuality, reference change value, and subject-based reference interval alleviated the concerns on his renal health and disparity in assay results (&lt;0.3 mg/dL≡ &lt;26.5 μmol/L) total allowable error limit), thus allowing intravenous contrast imaging.</div></div>","PeriodicalId":10172,"journal":{"name":"Clinical biochemistry","volume":"139 ","pages":"Article 110979"},"PeriodicalIF":2.5,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144674004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
DNA methylation levels are independently associated with prevalence of atherosclerotic cardiovascular disease in multifactorial chylomicronemia syndrome DNA甲基化水平与多因子乳糜微粒血症综合征中动脉粥样硬化性心血管疾病的患病率独立相关
IF 2.5 3区 医学 Q2 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2025-07-13 DOI: 10.1016/j.clinbiochem.2025.110978
Simon-Pierre Guay , Martine Paquette , Amélie Taschereau , Véronique Desgagné , Luigi Bouchard , Sophie Bernard , Alexis Baass

Background

Multifactorial chylomicronemia syndrome (MCS) is a form of severe hypertriglyceridemia (sHTG) associated with increased risk of acute pancreatitis and atherosclerotic cardiovascular disease (ASCVD). We recently reported suggestive evidence that DNA methylation (DNAm) contribute to the sHTG phenotype in MCS. While few predictors of acute pancreatitis were previously identified in MCS, predictors of ASCVD in MCS remain mostly unknown.

Objective

To study the factors associated with previous history of ASCVD in MCS patients.

Methods

A total of 114 patients with MCS were included in this retrospective study. Prevalence of ASCVD was determined at the baseline visit and defined as any atherosclerotic event: angina, myocardial infarction, coronary angioplasty, coronary bypass surgery, claudication, peripheral angioplasty, peripheral arterial surgery, transient ischemic attack, stroke, carotid endarterectomy, and artery stenosis (>50 %). DNAm level at ABCG1 (cg06500161), CPT1A (cg00574958), and SREBF1 (cg11024682) candidate gene loci was quantified using pyrosequencing of bisulfite-treated DNA.

Results

Univariate analysis showed that age, ABCG1 and SREBF1 DNAm level, and the presence of obesity, hypertension, diabetes, and maximal TG level > 40 mmol/L were associated with previous history of ASCVD. Multivariate analysis showed that age (OR 1.11 [1.04–1.18], p = 0.0006), SREBF1 DNAm levels (OR 1.12 [1.03–1.24], p = 0.01), the presence of a maximal TG level > 40 mmol/L (OR 0.13 [0.02–0.90], p = 0.04), and obesity (OR 3.32 [1.00–11.19, p = 0.05] were independently associated with history of ASCVD and explained 44.8 % of the variability in the prevalence of ASCVD (p < 0.0001).

Conclusion

This study shows that SREBF1 DNAm levels are independently associated with prevalence of ASCVD in MCS patients. It suggests that further studies of epivariations may contribute to better understand the clinical heterogeneity seen in MCS patients.
背景:多因素乳糜微粒血症综合征(MCS)是一种严重的高甘油三酯血症(sHTG),与急性胰腺炎和动脉粥样硬化性心血管疾病(ASCVD)的风险增加相关。我们最近报道了DNA甲基化(DNAm)有助于MCS中sHTG表型的启发性证据。虽然MCS中很少有急性胰腺炎的预测因素,但MCS中ASCVD的预测因素仍然未知。目的探讨MCS患者ASCVD病史的相关因素。方法回顾性分析114例MCS患者。在基线访问时确定ASCVD的患病率,并将其定义为任何动脉粥样硬化事件:心绞痛、心肌梗死、冠状动脉成形术、冠状动脉搭桥手术、跛行、外周血管成形术、外周动脉手术、短暂性脑缺血发作、中风、颈动脉内膜切除术和动脉狭窄(50%)。用焦磷酸测序法测定ABCG1 (cg06500161)、CPT1A (cg00574958)和SREBF1 (cg11024682)候选基因位点上的DNAm水平。结果单因素分析显示,年龄、ABCG1、SREBF1、DNAm水平、是否存在肥胖、高血压、糖尿病、最大TG水平与年龄、ABCG1、SREBF1、DNAm水平有关;40 mmol/L与既往ASCVD病史相关。多因素分析显示,年龄(OR为1.11 [1.04-1.18],p = 0.0006)、SREBF1 DNAm水平(OR为1.12 [1.03-1.24],p = 0.01)、是否存在最大TG水平和gt;40 mmol/L (OR 0.13 [0.02-0.90], p = 0.04)和肥胖(OR 3.32 [1.00-11.19, p = 0.05)与ASCVD病史独立相关,并解释了44.8%的ASCVD患病率变异性(p <;0.0001)。结论SREBF1 DNAm水平与MCS患者ASCVD患病率独立相关。这表明,进一步研究外变可能有助于更好地了解MCS患者的临床异质性。
{"title":"DNA methylation levels are independently associated with prevalence of atherosclerotic cardiovascular disease in multifactorial chylomicronemia syndrome","authors":"Simon-Pierre Guay ,&nbsp;Martine Paquette ,&nbsp;Amélie Taschereau ,&nbsp;Véronique Desgagné ,&nbsp;Luigi Bouchard ,&nbsp;Sophie Bernard ,&nbsp;Alexis Baass","doi":"10.1016/j.clinbiochem.2025.110978","DOIUrl":"10.1016/j.clinbiochem.2025.110978","url":null,"abstract":"<div><h3>Background</h3><div>Multifactorial chylomicronemia syndrome (MCS) is a form of severe hypertriglyceridemia (sHTG) associated with increased risk of acute pancreatitis and atherosclerotic cardiovascular disease (ASCVD). We recently reported suggestive evidence that DNA methylation (DNAm) contribute to the sHTG phenotype in MCS. While few predictors of acute pancreatitis were previously identified in MCS, predictors of ASCVD in MCS remain mostly unknown.</div></div><div><h3>Objective</h3><div>To study the factors associated with previous history of ASCVD in MCS patients.</div></div><div><h3>Methods</h3><div>A total of 114 patients with MCS were included in this retrospective study. Prevalence of ASCVD was determined at the baseline visit and defined as any atherosclerotic event: angina, myocardial infarction, coronary angioplasty, coronary bypass surgery, claudication, peripheral angioplasty, peripheral arterial surgery, transient ischemic attack, stroke, carotid endarterectomy, and artery stenosis (&gt;50 %). DNAm level at <em>ABCG1</em> (cg06500161), <em>CPT1A</em> (cg00574958), and <em>SREBF1</em> (cg11024682) candidate gene loci was quantified using pyrosequencing of bisulfite-treated DNA.</div></div><div><h3>Results</h3><div>Univariate analysis showed that age, <em>ABCG1</em> and <em>SREBF1</em> DNAm level, and the presence of obesity, hypertension, diabetes, and maximal TG level &gt; 40 mmol/L were associated with previous history of ASCVD. Multivariate analysis showed that age (OR 1.11 [1.04–1.18], p = 0.0006), <em>SREBF1</em> DNAm levels (OR 1.12 [1.03–1.24], p = 0.01), the presence of a maximal TG level &gt; 40 mmol/L (OR 0.13 [0.02–0.90], p = 0.04), and obesity (OR 3.32 [1.00–11.19, p = 0.05] were independently associated with history of ASCVD and explained 44.8 % of the variability in the prevalence of ASCVD (<em>p</em> &lt; 0.0001).</div></div><div><h3>Conclusion</h3><div>This study shows that <em>SREBF1</em> DNAm levels are independently associated with prevalence of ASCVD in MCS patients. It suggests that further studies of epivariations may contribute to better understand the clinical heterogeneity seen in MCS patients.</div></div>","PeriodicalId":10172,"journal":{"name":"Clinical biochemistry","volume":"139 ","pages":"Article 110978"},"PeriodicalIF":2.5,"publicationDate":"2025-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144632509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Low serum thyroglobulin level in A 15-year-old girl with papillary thyroid cancer and multiple neck lymph nodes: a case report 15岁女童甲状腺乳头状癌伴多发颈部淋巴结低血清甲状腺球蛋白1例。
IF 2.5 3区 医学 Q2 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2025-07-13 DOI: 10.1016/j.clinbiochem.2025.110977
Nawroz Barwari, Alina-Gabriela Sofronescu

Background

Papillary thyroid carcinoma (PTC) is the most common form of differentiated thyroid cancer. Serum thyroglobulin (Tg) is a key biomarker used in postoperative surveillance. However, discrepancies between Tg levels and disease burden may occur, complicating clinical assessment. The report herein proposes to discuss such a case.

Case presentation

We present a case of a 15-year-old girl with a history of total thyroidectomy for PTC (age 13) who developed a new vascular neck mass. Sonographic and cytologic evidence confirmed metastasis. Serum Tg levels (evaluated using concurrent immunoassays and liquid chromatography – tandem mass spectrometry) were detectable, but not proportional to the extent of disease burden, while the fine-needle aspirate (FNA) Tg levels were markedly elevated, consistent with metastatic disease.

Discussion

This case illustrates a phenomenon in which the degree of Tg elevation in serum is not proportional to the extent of metastatic disease. We discuss the analytical and biological factors that can contribute to this discordance and highlight the importance of multimodal monitoring strategies.

Conclusion

Clinicians should be aware that any detectable serum Tg in athyreotic patients indicates residual thyroid tissue or disease. However, this might not necessarily correlate well with the degree of metastatic disease. The integration of imaging, FNA cytology, and aspirate Tg measurement is essential for accurate disease assessment, particularly in cases with discordant laboratory findings.
背景:甲状腺乳头状癌(PTC)是最常见的分化型甲状腺癌。血清甲状腺球蛋白(Tg)是术后监测的关键生物标志物。然而,Tg水平与疾病负担之间可能存在差异,使临床评估复杂化。本报告拟讨论这种情况。病例介绍:我们报告了一个15岁的女孩,她有甲状腺全切除术的PTC病史(13岁),她出现了一个新的血管性颈部肿块。超声和细胞学证实有转移。血清Tg水平(使用同步免疫测定和液相色谱-串联质谱法评估)可检测到,但与疾病负担程度不成比例,而细针抽吸(FNA) Tg水平明显升高,与转移性疾病一致。讨论:本病例说明了血清中Tg升高的程度与转移性疾病的程度不成比例的现象。我们讨论了可能导致这种不一致的分析和生物学因素,并强调了多模式监测策略的重要性。结论:临床医生应该意识到,任何可检测到的甲亢患者血清Tg表明残留的甲状腺组织或疾病。然而,这可能并不一定与转移性疾病的程度密切相关。影像学、FNA细胞学和抽吸Tg测量的整合对于准确的疾病评估至关重要,特别是在实验室结果不一致的情况下。
{"title":"Low serum thyroglobulin level in A 15-year-old girl with papillary thyroid cancer and multiple neck lymph nodes: a case report","authors":"Nawroz Barwari,&nbsp;Alina-Gabriela Sofronescu","doi":"10.1016/j.clinbiochem.2025.110977","DOIUrl":"10.1016/j.clinbiochem.2025.110977","url":null,"abstract":"<div><h3>Background</h3><div>Papillary thyroid carcinoma (PTC) is the most common form of differentiated thyroid cancer. Serum thyroglobulin (Tg) is a key biomarker used in postoperative surveillance. However, discrepancies between Tg levels and disease burden may occur, complicating clinical assessment. The report herein proposes to discuss such a case.</div></div><div><h3>Case presentation</h3><div>We present a case of a 15-year-old girl with a history of total thyroidectomy for PTC (age 13) who developed a new vascular neck mass. Sonographic and cytologic evidence confirmed metastasis. Serum Tg levels (evaluated using concurrent immunoassays and liquid chromatography – tandem mass spectrometry) were detectable, but not proportional to the extent of disease burden, while the fine-needle aspirate (FNA) Tg levels were markedly elevated, consistent with metastatic disease.</div></div><div><h3>Discussion</h3><div>This case illustrates a phenomenon in which the degree of Tg elevation in serum is not proportional to the extent of metastatic disease. We discuss the analytical and biological factors that can contribute to this discordance and highlight the importance of multimodal monitoring strategies.</div></div><div><h3>Conclusion</h3><div>Clinicians should be aware that any detectable serum Tg in athyreotic patients indicates residual thyroid tissue or disease. However, this might not necessarily correlate well with the degree of metastatic disease. The integration of imaging, FNA cytology, and aspirate Tg measurement is essential for accurate disease assessment, particularly in cases with discordant laboratory findings.</div></div>","PeriodicalId":10172,"journal":{"name":"Clinical biochemistry","volume":"139 ","pages":"Article 110977"},"PeriodicalIF":2.5,"publicationDate":"2025-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144641925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Clinical biochemistry
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1